Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Aprocitentan in Healthy Japanese and Caucasian Subjects
NCT03586570Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in resistant hypertension (RH) comparing Aprocitentan with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 1 more. Started Jul 2018; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT03586570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586570.